Evidence map›Paper›PMID 27303909›Full record

ArticleGenetics and molecular biology

Cardanol: toxicogenetic assessment and its effects when combined with cyclophosphamide.

Beatriz Ursinos Catelan Schneider, Alisson Meza, Adilson Beatriz, João Renato Pesarini, Pamela Castilho de Carvalho, Mariana de Oliveira Mauro, Caroline Bilhar Karaziack, Andréa Luiza Cunha-Laura, Antônio Carlos Duenhas Monreal, Renata Matuo and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetics and molecular biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
6.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 22 citations in OpenAlex.

  1. The Potential ofMolecules (Basel, Switzerland) · 2023
    Review
  2. The Ethanolic Extract ofPharmaceutics · 2022
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Beatriz Ursinos Catelan SchneiderPrograma de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta", Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Alisson MezaPrograma de Pós-Graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Adilson BeatrizPrograma de Pós-Graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
João Renato PesariniPrograma de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta", Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Pamela Castilho de CarvalhoPrograma de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta", Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Mariana de Oliveira MauroPrograma de Doutorado em Biotecnologia e Biodiversidade - Rede Pró Centro-Oeste, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Caroline Bilhar KaraziackPrograma de Pós-Graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Andréa Luiza Cunha-LauraPrograma de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Antônio Carlos Duenhas MonrealPrograma de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Renata MatuoCentro de Estudos em Células-Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", Empresa Brasileira de Serviços Hospitalares, Campo Grande, MS, Brazil.
Dênis Pires de LimaPrograma de Pós-Graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Rodrigo Juliano OliveiraPrograma de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta", Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Universidade Federal de Mato Grosso do Sul · BRHospital Universitário de Santa Maria · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardanol is an effective antioxidant and is a compound with antimutagenic and antitumoral activity. Here, we evaluated the genotoxic and mutagenic potential of saturated side chain cardanol and its effects in combination with cyclophosphamide in preventing DNA damage, apoptosis, and immunomodulation. Swiss mice were treated with cardanol (2.5, 5 and 10 mg/kg) alone or in combination with cyclophosphamide (100 mg/kg). The results showed that cardanol is an effective chemopreventive compound, with damage reduction percentages that ranged from 18.9 to 31.76% in the comet assay and from 45 to 97% in the micronucleus assay. Moreover, cardanol has the ability to reduce the frequency of apoptosis induced by cyclophosphamide. The compound did not show immunomodulatory activity. A final interpretation of the data showed that, despite its chemoprotective capacity, cardanol has a tendency to induce DNA damage. Hence, caution is needed if this compound is used as a chemopreventive agent. Also, this compound is likely not suitable as an adjuvant in chemotherapy treatments that use cyclophosphamide.

Identifiers

PMID27303909
PMCPMC4910563
OpenAlexW2414144765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.